• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Books/CDs/Prayer Cards
        • CR Media platforms
        • Electronic Edition
  • Advertising
  • Shop
        • Purchase Photos
        • Books/CDs/Prayer Cards
        • Magazine Subscriptions
        • Archdiocesan Directory
  • Radio/Podcasts
        • Catholic Review Radio
        • Protagonistas de Fe
        • In God’s Image
  • News Tips
  • Subscribe
Mifepristone, the first medication in a chemical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Ill., April 20, 2023. The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug's availability. (OSV News photo/Evelyn Hockstein)

Supreme Court is asked to weigh in on future of abortion pill

September 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, Supreme Court, World News

WASHINGTON (OSV News) — The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower-court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug’s availability.

A coalition of pro-life opponents of mifepristone, the first of two drugs used in a medication or chemical abortion, previously filed suit in an effort to revoke the U.S. Food and Drug Administration’s approval of the drug, arguing the government violated its own safety standards when it first approved the drug in 2000.

However, proponents argued mifepristone poses statistically little risk to women using it for abortion early in pregnancy and claim the drug is being singled out for political reasons.

In its filing on behalf of the FDA, the Justice Department called the appeals court ruling an “unprecedented decision,” arguing its logic “would threaten to severely disrupt the pharmaceutical industry and prevent FDA from fulfilling its statutory responsibilities according to its scientific judgment.”

The filing argued the drug is safe and that “study after study” has shown “serious adverse events are exceedingly rare” when mifepristone is taken under the approved conditions. The filing added, “For many patients, mifepristone is the best method to lawfully terminate their early pregnancies.”

It stated that revoking approval of the pill “would be damaging for women and health care providers around the Nation.”

But in a statement, Erik Baptist, senior counsel for Alliance Defending Freedom, which is representing the pro-life coalition challenging mifepristone’s approval, said the FDA “has been entrusted to serve as the nation’s gatekeeper of legal drugs.”

“By repeatedly and unlawfully removing critical safeguards in the chemical abortion regimen, the FDA has failed to protect the safety of women and girls,” he said. “Two courts have now held the FDA accountable for the damage it has done to the rule of law and the harm it has caused to countless girls and women. We hope the Supreme Court does the same.”

Earlier this year, the Supreme Court blocked a lower court’s restrictions on mifepristone, leaving the abortion pill on the market while litigation proceeds. That decision froze the lower court’s ruling to stay the FDA’s approval of the drug.

The Justice Department and Danco, the pharmaceutical company that manufactures mifepristone, previously asked the Supreme Court to intervene in the case after an appeals court allowed portions of the ruling by U.S. District Judge Matthew Kacsmaryk to take effect.

In a Sept. 8 statement, Danco said it “continues to be at the forefront of this fight and is working closely with the reproductive rights community and pharmaceutical industry to support the changes made by FDA.”

Should the Supreme Court take the case, it would likely be added to its docket in its coming term.

The two-drug chemical abortion regimen is currently legal in some form in 36 states and the District of Columbia. It is permitted in 21 states, but with some additional restrictions in the remaining 15, according to data from the Guttmacher Institute, which supports abortion access.

The Catholic Church opposes abortion, teaching that all human life is sacred from conception to natural death and that society must extend support to mothers and children. Earlier this year, Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, denounced Biden administration’s attempts to loosen regulations around the abortion bill, saying the U.S. bishops “decry the continuing push for the destruction of innocent human lives and the loosening of vital safety standards for vulnerable women.”

A link to the Justice Department’s filing is here: https://s3.documentcloud.org/documents/23945337/usfda-et-al-v-alliance-for-hippocratic-medicine-et-al-petition.pdf.

Read More Respect Life

Pro-life groups urge DOJ to stop opposing state abortion pill lawsuits

DOJ report accuses Biden administration of ‘weaponizing’ prosecutions of pro-life activists

Latest Planned Parenthood report: abortions and taxpayer funding up, cancer screenings down

Judge pauses state’s abortion pill lawsuit until FDA completes timely safety review

Fired Planned Parenthood whistleblower addresses Maryland March for Life

Missouri bishops back amendment to limit abortion, gender transition for minors

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • St. Michael-St. Clement School will close at end of academic year
  • Trump lashes out at Pope Leo amid Iran war rebuke
  • Trump draws backlash over Pope Leo rant, ‘deeply offensive’ image of him looking like Christ
  • Trump administration ends contract with Miami Catholic Charities to shelter unaccompanied minors
  • US bishops’ doctrine chair defends Church’s just war tradition after Vance comments

| Latest Local News |

2026 Distinctive Scholars recognized

Sister Marie Anna (Rose de Lima) Stelmach, O.P., dies at 80 

Archbishop Lori urges respect, dialogue after Trump-pope tensions

Catholics nurture environment in gardens, yards and beyond

Xaverian Brother Charles Warthen dies at 92

| Latest World News |

Pope Leo year one: How Chiclayo’s bishop brought his grounded leadership to global church

Pope Leo named one of Time magazine’s ‘100 Most Influential People of 2026’

With candor, Pope Leo confronts Cameroon’s ongoing abductions, killings in plea for peace

Vatican ends canonization cause for Jesuit Father Walter Ciszek

Pope Leo tells African students AI revolution risks changing ‘our very relationship with truth’

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Pope Leo year one: How Chiclayo’s bishop brought his grounded leadership to global church
  • New York Gov. Al Smith: Perseverance in both political endeavors, faith
  • Pope Leo named one of Time magazine’s ‘100 Most Influential People of 2026’
  • With candor, Pope Leo confronts Cameroon’s ongoing abductions, killings in plea for peace
  • Vatican ends canonization cause for Jesuit Father Walter Ciszek
  • Pope Leo tells African students AI revolution risks changing ‘our very relationship with truth’
  • Pope Leo XIV celebrates Mass with 120,000 people in Cameroon: ‘Bring the bread of life to your neighbors’
  • 2026 Distinctive Scholars recognized
  • Movie Review: ‘Peaky Blinders: The Immortal Man’

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED